285
Views
4
CrossRef citations to date
0
Altmetric
Articles

Comparison of psychotropic medication use in the Baltic countries

, , , , , , , , , , , & show all
Pages 301-306 | Received 03 Jul 2019, Accepted 13 Dec 2019, Published online: 31 Dec 2019

References

  • Ban TA. A history of the Collegium Internationale Neuro-Psychopharmacologicum (1957-2004. Prog Neuro-Psychopharmacol Biol Psychiatr. 2006;30(4):599–616.
  • Millan MJ, Goodwin GM, Meyer-Lindenberg A, et al. Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders. Eur Neuropsychopharmacol. 2015;25(5):599–656.
  • Zohar J, Kasper S. Neuroscience-based Nomenclature (NbN): a call for action. World J Biol Psychiatry. 2016;17(5):318–320.
  • Abbott A. Schizophrenia: the drug deadlock. Nature. 2010;468(7321):158–159.
  • Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. CPD. 2009;15(14):1563–1586.
  • Balter MB, Levine J, Manheimer DI. Cross-national study of the extent of anti-anxiety-sedative drug use. N Engl J Med. 1974;290(14):769–774.
  • Balter MB, Manheimer DI, Mellinger GD, et al. A cross-national comparison of anti-anxiety/sedative drug use. Curr Med Res Opin. 1984;8(S4):5–20.
  • Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France Germany, Italy, and the United Kingdom. J Clin Psychiatr. 2002;63(9):817–825.
  • Zito JM, Safer DJ, de Jong – v, den Berg LT, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008;2(1):26.
  • Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003;157(1):17–25.
  • Hoebert JM, Mantel-Teeuwisse AK, Leufkens HGM, et al. Variability in market uptake of psychotropic medications in Europe reflects cultural diversity. BMC Health Serv Res. 2017;17(1):702.
  • Wagemaakers FN, Hollingworth SA, Kreijkamp-Kaspers S, et al. Opioid analgesic use in Australia and The Netherlands: a cross-country comparison. Int J Clin Pharm. 2017;39(4):874–880.
  • Bauer M, Monz BU, Montejo AL, et al. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatr. 2008;23(1):66–73.
  • Kasekamp A. A History of the Baltic States. Basingstoke: Palgrave Macmillan; 2010.
  • Lauristin M, Vihalemm P, Rosengren KE, Weibull L, editors. Return to the Western World. Estonia: Tartu University Press; 1997.
  • WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification System. Available from: www.whocc.no/atc_ddd_index.
  • Baltic Statistics on Medicines 2010–2012. Riga. 2013.
  • Baltic Statistics on Medicines 2013–2015. Riga. 2016.
  • The Danish Health Data Authority. [cited 2018 Nov 1]. Available from: http://www.medstat.dk/en.
  • Suomen Lääketilasto/Finnish Statistics on Medicines 2015. Finnish Medicines Agency Fimea and Social Insurance Institution. Helsinki 2016.
  • Sakshaug S. Legemiddelforbruket i Norge 2012-2016 [Drug Consumption in Norway 2012-2016], Legemiddelstatistikk 2017:1. Oslo: Folkehelseinstituttet, 2017.
  • Socialstyrelsen. [cited 2018 Nov 1]. Available from: http://www.socialstyrelsen.se/publikationer2016/2016-4-25.
  • Morrens M, Destoop M, Cleymans S, et al. Evolution of first-generation and second-generation antipsychotic prescribing patterns in Belgium between 1997 and 2012: a population-based study. J Psychiatr Pract. 2015;21(4):248–258.
  • Arias LHM, Lobato CT, Garcia SP, et al. Impact of regulatory measures on antipsychotics drug consumption in Castilla y Léon Spain. Public Health. 2016;141:113–119.
  • Huerta C, Abbing-Karahagopian V, Requena G, et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU project. Pharmacoepidemiol Drug Saf. 2016; 25 (S1):56–65.
  • Potocnjak I, Likic R, Degoricija V, et al. The benzodiazepine nation of Croatia: An observational, comparative study of psychotropic drug utilization between Croatia and Sweden 2014-2015. Expert Rev Pharmacoecon Outcomes Res. 2018;18:641–646.
  • Sonn K, Laius O, Irs A. Hypnotics – clinical pharmacology and utilization trends in Estonia (in Estonian). Eesti Arst. 2015;94:684–688.
  • Patten SB, Williams JVA, Lavorato DH, et al. Antidepressant use in Canada has stopped increasing. Can J Psychiatr. 2014;59(11):609–614.
  • Pharoah PD, Melzer D. Variation in prescribing of hypnotics, anxiolytics and antidepressants between 61 general practices. Br J General Prac. 1995;45(400):595–599.
  • Tsimtsiou Z, Ashworth M, Jones R. Variations in anxiolytic and hypnotic prescribing by GPs: a cross-sectional analysis using data from the UK Quality and Outcomes Framework. Br J Gen Pract. 2009;59(563):e191–e198.
  • De Las Cuevas C, Motuca M, Baptista T, et al. Skepticism and pharmacophobia toward medication may negatively impact adherence to psychiatric medications: a comparison among outpatient samples recruited in Spain, Argentina, and Venezuela. Patient Prefer Adherence. 2018;12:301–310.
  • Põlluste K, Kasiulevičius V, Veide S, et al. Primary care in Baltic countries: a comparison of progress and present systems. Health Policy. 2013;109(2):122–130.,
  • Lithuanian Psychiatric Association. [cited 2019 Jun 25]. Available from: https://www.psichiatrija.lt/en/news/.
  • Puras D. Iššūki a i įgyvendinant L ietuvos ps i chikos sveikatos politiką. ISBN 978-609-459-279-9; Vilnius University Press, 2013. 68, p. 83–115.
  • Demyttenaere K, Bonnewyn A, Bruffaerts R, et al. Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD. J Affect Disorders. 2008;110(1–2):84–93.
  • Wettermark B, Zoega H, Furu K, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research – a literature review. Pharmacoepidemiol Drug Saf. 2013;22(7):691–699.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.